Chattem’s ACT goes global
This article was originally published in The Tan Sheet
Executive Summary
The Chattanooga, Tenn.-based firm announces an agreement May 7 to acquire the Western Europe rights to ACTas well as worldwide trademark rights from Johnson & Johnson for $4.1 mil. plus certain assumed liabilities. The European Commission approved the transaction and the deal is expected to close in late May. J&J is divesting ACT as a condition of the EC's approval of J&J's Pfizer Consumer Healthcare acquisition and "certain regulatory requirements in connection with the acquisition in Greece," the firm says. Chattem acquired ACT and five other OTC brands from J&J/Pfizer in January 2007 (1"The Tan Sheet" Feb. 19, 2007, p. 10)...
You may also be interested in...
Global ACT deal closes
Chattem announces May 29 the closing of an agreement to acquire the rights to anti-cavity mouthwash ACT in Western Europe together with worldwide trademark rights for $4.1 mil. and assumed liabilities. The Chattanooga, Tenn.-based firm announced the agreement May 7 after the European Commission approved it (1"The Tan Sheet" May 14, 2007, In Brief). Chattem acquired ACT and other brands in January 2007 as Johnson & Johnson divested brands in connection with its Pfizer Consumer Healthcare purchase (2"The Tan Sheet" Feb. 19, 2007, p. 10)...
Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy
For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”